For instance, splicing factor mutation‐bearing cancers are predominantly dependent on the function of the wild‐type spliceosome and are sensitive to the global inhibition of splicing with derivatives of pladienolides, spliceostatins and herboxidienes, resulting in a preferential death of mutant cancer cells. This evidence concerns the gene SLU7 and cancer.